Company profile for FibroGen

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We work at the intersection of groundbreaking science and patient need. Our research and development teams seek to identify and develop innovative drugs with the greatest promise of becoming first-in-class medicines for the treatment of chronic and life-threatening conditions such as anemia, idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy. Our product candidates leverage the body’s natural p...
We work at the intersection of groundbreaking science and patient need. Our research and development teams seek to identify and develop innovative drugs with the greatest promise of becoming first-in-class medicines for the treatment of chronic and life-threatening conditions such as anemia, idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy. Our product candidates leverage the body’s natural pathways, providing us with the scientific insight to investigate their potential across multiple diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
409 Illinois Street San Francisco, CA 94158
Telephone
Telephone
+1 415.978.1200
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/10/3185020/33525/en/FibroGen-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html

GLOBENEWSWIRE
10 Nov 2025

https://www.globenewswire.com/news-release/2025/11/03/3179766/33525/en/FibroGen-to-Report-Third-Quarter-2025-Financial-Results.html

GLOBENEWSWIRE
03 Nov 2025

https://www.globenewswire.com/news-release/2025/09/24/3155319/33525/en/FibroGen-Initiates-Phase-2-Monotherapy-Trial-of-FG-3246-a-First-in-Class-CD46-Targeting-ADC-in-Metastatic-Castration-Resistant-Prostate-Cancer.html

GLOBENEWSWIRE
24 Sep 2025

https://www.fiercepharma.com//www.fiercebiotech.com/biotech/fibrogen-pays-sec-12m-over-allegations-former-exec-reverse-engineered-roxadustat-data

FIERCE PHARMA
11 Sep 2025

https://www.globenewswire.com/news-release/2025/09/02/3142499/33525/en/FibroGen-Completes-Sale-of-FibroGen-China-to-AstraZeneca-for-Approximately-220-Million.html

GLOBENEWSWIRE
02 Sep 2025

https://www.globenewswire.com/news-release/2025/08/27/3140347/33525/en/FibroGen-to-Present-at-the-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html

GLOBENEWSWIRE
27 Aug 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty